Avadel Pharmaceuticals Management

Management criteria checks 4/4

Avadel Pharmaceuticals' CEO is Greg Divis, appointed in Jan 2019, has a tenure of 5.25 years. total yearly compensation is $753.69K, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €2.54M. The average tenure of the management team and the board of directors is 4.7 years and 5.8 years respectively.

Key information

Greg Divis

Chief executive officer

US$753.7k

Total compensation

CEO salary percentage	74.5%
CEO tenure	5.3yrs
CEO ownership	0.2%
Management average tenure	4.7yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Greg Divis's remuneration changed compared to Avadel Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$160m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$142m
Dec 31 2022	US$754k	US$561k	-US$137m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	-US$90m
Dec 31 2021	US$3m	US$545k	-US$77m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$3m	US$520k	US$7m
Sep 30 2020	n/a	n/a	US$16m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$1m	US$472k	-US$33m
Sep 30 2019	n/a	n/a	-US$94m
Jun 30 2019	n/a	n/a	-US$101m
Mar 31 2019	n/a	n/a	-US$96m
Dec 31 2018	US$685k	US$417k	-US$95m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	US$30m
Dec 31 2017	US$1m	US$375k	US$68m

Compensation vs Market: Greg's total compensation ($USD753.69K) is below average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.

CEO

Greg Divis (56 yo)

5.3yrs

Tenure

US$753,687

Compensation

Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gregory Divis	CEO & Director	5.3yrs	US$753.69k	0.18% $ 2.5m
Thomas McHugh	Senior VP	4.3yrs	US$526.00k	0.089% $ 1.3m
Richard Kim	Chief Commercial Officer	3.2yrs	US$548.44k	0% $ 0
Jerad Seurer	General Counsel & Company Secretary	no data	no data	no data
Gregory Davis	VP of Corporate and Business Development	8.8yrs	no data	0.054% $ 785.3k
Mark Elrod	Vice President of Sales	7.7yrs	no data	no data
Angie Woods	Vice President of People & Culture	2.9yrs	no data	no data
Jordan Dubow	Consultant	5yrs	US$982.54k	no data
Jason Vaughn	Senior Vice President of Technical Operations	4.3yrs	no data	no data
Jennifer Gudeman	Senior Vice President of Medical & Clinical Affairs	no data	no data	no data

4.7yrs

Average Tenure

56yo

Average Age

Experienced Management: AWK1's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gregory Divis	CEO & Director	4.8yrs	US$753.69k	0.18% $ 2.5m
Jean-Marie Lehn	Member of Scientific Advisory Board	19.3yrs	no data	no data
Mark McCamish	Independent Director	4.3yrs	US$227.53k	0.074% $ 1.1m
Peter Thornton	Independent Director	6.8yrs	US$237.53k	0.092% $ 1.3m
Christian Trepo	Member of Scientific Advisory Board	19.3yrs	no data	no data
Patrick Couvreur	Member of Scientific Advisory Board	no data	no data	no data
Eric Ende	Independent Director	5.3yrs	US$230.03k	0.19% $ 2.7m
Catherine Bréchignac	Chairman of Scientific Advisory Board	no data	no data	no data
Geoffrey Glass	Independent Non-Executive Chairman of the Board	5.8yrs	US$257.12k	0.14% $ 2.0m
Linda Palczuk	Independent Director	5.8yrs	US$230.03k	0.058% $ 838.0k

5.8yrs

Average Tenure

59yo

Average Age

Experienced Board: AWK1's board of directors are considered experienced (5.8 years average tenure).

Avadel Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Insufficient new directors

Independent Director recently sold €984k worth of stock

Key Executive recently bought €170k worth of stock

Insufficient new directors

Insufficient new directors

Independent Director recently bought €152k worth of stock

Recent updates

Insufficient new directors

Forecast to breakeven in 2025

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold €984k worth of stock

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

New minor risk - Insider selling

Key Executive recently bought €170k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Insufficient new directors

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Independent Director recently bought €152k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals Provides Corporate Update

Senior VP & CFO recently bought €100k worth of stock

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Avadel Pharmaceuticals plc, Annual General Meeting, Aug 04, 2022

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 Rest-On Trial

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP

Avadel Pharmaceuticals plc Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021

Avadel Pharmaceuticals plc to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021

Jazz Pharmaceuticals, Inc. Files Compliant Against Avadel Pharmaceuticals plc

Investor sentiment improved over the past week

Revenue beats expectations

Full year 2020 earnings released: EPS US$0.13 (vs US$0.89 loss in FY 2019)

Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies

New 90-day high: €7.35

Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer

New 90-day high: €7.00

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Avadel Pharmaceuticals plc Announces Submission of New Drug Application for FT218 to the FDA

New 90-day high: €6.70

Investor sentiment improved over the past week

Market bids up stock over the past week

Market bids up stock over the past week

Revenue in line with expectations

Market bids up stock over the past week

Avadel Pharmaceuticals plc to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €4.14

Independent Director recently bought €83k worth of stock

New 90-day low: €4.32

New 90-day low - €5.90

Avadel Pharmaceuticals plc to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €6.50

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age